ERBB2 and breast carcinoma: Several RCTs have confirmed the usefulness of trastuzumab for patients with HER2-positive breast cancer in the metastatic (Slamon et al, 2001) and adjuvant setting (Piccart-Gebhart et al, 2005; Romond et al, 2005; Smith et al, 2007).